Edwards Lifesciences Corporation
EW · NYSE
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $2 | $2 | $1 | $1 |
| % Growth | 1.4% | 8.5% | 1.9% | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $1 | $1 | $1 | $1 |
| % Margin | 77.9% | 77.6% | 78.7% | 78.9% |
| R&D Expenses | $0 | $0 | $0 | $0 |
| G&A Expenses | $0 | $0 | $0 | $0 |
| SG&A Expenses | $1 | $1 | $0 | $0 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | -$0 | -$0 | -$0 | $0 |
| Operating Expenses | $1 | $1 | $1 | $1 |
| Operating Income | $0 | $0 | $0 | $0 |
| % Margin | 27.4% | 28.1% | 27.9% | 22.6% |
| Other Income/Exp. Net | -$0 | -$0 | $0 | $0 |
| Pre-Tax Income | $0 | $0 | $0 | $0 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | $0 | $0 | $0 | $0 |
| % Margin | 18.7% | 21.5% | 25.3% | 27.8% |
| EPS | 0.5 | 0.57 | 0.61 | 0.65 |
| % Growth | -12.3% | -6.6% | -6.2% | – |
| EPS Diluted | 0.5 | 0.56 | 0.61 | 0.65 |
| Weighted Avg Shares Out | 1 | 1 | 1 | 1 |
| Weighted Avg Shares Out Dil | 1 | 1 | 1 | 1 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | $0 | $0 | $0 | $0 |
| % Margin | 25% | 26.1% | 33.3% | 34.9% |